Business UpdateJul 7, 2026, 08:57 AM
bioAffinity CyPath® Lung Sales Double to New Record in Q2
AI Summary
bioAffinity Technologies announced continued acceleration in commercial sales for its noninvasive lung cancer diagnostic, CyPath® Lung, with over 200% year-over-year growth in Q2 2026. Sales volume also increased more than 30% compared to the previous quarter, driven by a 155% rise in physician offices ordering the test. The company has now performed nearly 3,000 CyPath® Lung tests since its commercial launch and is expanding its clinical impact with new initiatives, including monitoring lung cancer survivors and developing diagnostics for asthma and COPD.
Key Highlights
- CyPath® Lung sales volume grew over 200% year-over-year in Q2 2026.
- Sales volume increased more than 30% over the record-breaking prior quarter (Q1 2026).
- Physician offices ordering CyPath® Lung increased by 155% compared to Q2 2025.
- Nearly 3,000 CyPath® Lung tests have been performed since commercial launch.
- Company is expanding into oncology for monitoring lung cancer survivors.
- R&D pipeline includes diagnostic tests for asthma and COPD.
Price Impact
More from BIAF